Noticias y eventos de Kymera Therapeutics Inc (KYMR)KYMRKymera Therapeutics Inc

Kymera Therapeutics Q2 Revenue $65M, Exceeds Expectations

Reports Q2 revenue $65M, consensus $32.78M. Collaboration revenues recognized in the second quarter of 2026 consisted of a $45M option exercise fee related to the company's collaboration with Gilead Sciences and a $20M milestone payment related to the company's collaboration with Sanofi. "Kymera is delivering in a pivotal period of execution, with multiple clinical-stage programs advancing, important data catalysts ahead, and growing conviction in the potential of oral degrader medicines to transform the standard of care for chronic, debilitating immunological diseases," said Nello Mainolfi, Founder, President and CEO, Kymera Therapeutics. "The rapid completion of enrollment in our KT-621 BROADEN2 Phase 2b trial in atopic dermatitis nearly six months ahead of our original timeline is a powerful example of the immense interest from clinicians and patients in a once-daily oral therapy and excellent execution from the Kymera team. The accelerated timeline enables us to pull forward our expected topline readout to year-end 2026, positions us for an earlier than anticipated start to Phase 3 trials next year, and ultimately allows us to move faster for patients who are waiting for new options."

Kymera Therapeutics Appoints Terence Rooney as Chief Medical Officer

Kymera Therapeutics announced the appointment of Terence Rooney as chief medical officer. Rooney is an accomplished drug development leader with extensive experience advancing immunology therapies across the full development lifecycle, from early clinical stages through commercialization and franchise expansion, helping bring important new medicines to patients around the world. In his role, Rooney will lead Kymera's global clinical development strategy and guide the advancement of the company's oral immunology portfolio across multiple immuno-inflammatory diseases. He succeeds Jared Gollob, who will retire from his role after eight years with the company and will remain as an advisor through the end of the year.

Nasdaq Declines Despite Strong Micron Earnings Report

The major averages had a mixed but mostly unchanged session, with the Nasdaq leading the way lower even after a strong Micron earnings report. Investors had started questioning whether the AI trade was losing momentum, but the latest chip demand signals are pushing the narrative back toward continued infrastructure expansion.Meanwhile, The Wall Street Journal reported that Iran has attacked a Singapore-flagged cargo ship traveling through the Strait of Hormuz. The attack inflicted damage on the ship's bridge but left no casualties, according to U.K. Maritime Trade Operations.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Micronreportedand provided upbeat Q4 earnings guidanceQualcommraised its FY29Multiple big banks, including JPMorgan, Goldman Sachs, and Wells Fargo, announced new capital return plans, such as higher dividends and share buybacks, after theits stress test confirms large banks are "well positioned" for a severe recession scenarioMerck KGaABio-Technefor $73 per share in cashAppleis raising prices on2. WALL STREET CALLS:Qualcommto Equal Weight at Morgan Stanley after investor day forecastsPVH Corp.to Underperform at BofA on high EMEA exposureIntelwith a Neutral at Goldman SachsBarclaysKeurig Dr Pepperon upside into separationMorgan StanleyAffirmto Equal Weight on "valuation call"3. AROUND THE WEB:Appleis planning a major shift in its Mac chip roadmap by launching a base M6 chip for entry-level Macs as early as this year while skipping M6 Pro and Max variants, Bloomberg reportsSonoswill cut an additional 3% of its workforce, Bloomberg saysKalshi is in discussions to raise new funding at an approximately $40B valuation and could close the round as early as the third quarter of this year as it expands prediction market offerings and competes more directly with major derivatives and gambling companies, FT reportsAccording to a letter from the U.S. FDA, Amgen'sChemoCentryx personnel "manipulated" study data to make Tavneos, a pill made to treat a rare blood vessel disorder, appear more effective, Bloomberg saysBlue Owl Capitalis in advanced talks to buy a minority stake in the NBA's Cleveland Cavaliers through the private equity firm's Blue Owl's Dyal HomeCourt Partners fund, Bloomberg says4. MOVERS:BlackBerryincreases in New York afterand providing guidance for Q2 and FY27Kymera Therapeuticsgains afterfor its BROADEN2 trialAtaiBeckleyhigher afterit will be added to the Russell 2000 and Russell 3000 Indexes at open on June 29Trip.comlower in New York afterand providing guidance for Q2Hive Digitalfalls after announcing a private offering ofdue 20315. EARNINGS/GUIDANCE:McCormickand backed its guidance for FY26Commercial Metals, with CEO Peter Matt commenting, "We continued to make great progress on our strategic agenda across a number of fronts"TD Synnexand provided guidance for Q3Acuity Brands, with CEO Neil Ashe commenting, "We demonstrated solid execution in our third quarter of fiscal 2026"Winnebago, with EPS and revenue missing consensusINDEXES:The Dow rose 71.72, or 0.14%, to 51,920.62, the Nasdaq lost 118.03, or 0.46%, to 25,358.60, and the S&P 500 declined 0.73, or 0.0099%%, to 7,357.49.